• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Topics » General Psychiatry

General Psychiatry
General Psychiatry RSS Feed RSS

A Boatload of New Data on Stimulants and Cardiac Events

February 1, 2012
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
In 2006, an FDA panel recommended all manufacturers of stimulants to add a “black box” warning about an increased risk of “serious cardiovascular events.”
Read More

Diagnosis and Treatment of ADHD in Adults

February 1, 2012
Aashish Parikh, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Aashish Parikh, MD Assistant professor of psychiatry, The University of Texas Southwestern Medical School Dr. Parikh has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
To begin with, you have to specify whether you are thinking in terms of DSM-IV criteria or probable DSM-5 criteria. The major difference is that currently you have to establish that ADHD symptoms began before age seven, whereas DSM-5 is more lenient, requiring that they began by age 12.
Read More

Is Pharmacogenetic Testing Used—and Useful—in Clinical Practice?

February 1, 2012
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
For years, we have read articles about the promise of pharmacogenetic testing to help us choose and monitor medication treatment.
Read More

How Risky is Pregnancy for Women with a History of Mood Disorders?

February 1, 2012
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
We know that the postpartum period is a risky time for women who have a history of depression, especially if they experienced postpartum depression in the past. But several questions about mood and pregnancy are still unanswered.
Read More

FDA Publishes Article Critical of Vilazodone Data

February 1, 2012
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
It has been over a year now since the approval of vilazodone (Viibryd). As you may recall from our review of the drug in TCPR April 2011, vilazodone is an SSRI with partial agonism at the 5HT1A receptor.
Read More

Learning Objectives, ADHD, TCPR, February 2012

February 1, 2012
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
After reading these articles, you should be able to…
Read More

Deplin: Is it Just Folate by Another Name?

January 1, 2012
Steve Balt, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Steve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb.
Patients are probably asking you about Deplin, or L-methylfolate, a version of folic acid that is being marketed by Pamlab as an adjunctive treatment for depression.
Read More

Nuedexta for Pseudobulbar Affect

January 1, 2012
Steve Balt, MD and Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Steve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb. Daniel Carlat, MD
Editor-in-Chief, Publisher, The Carlat Report.
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Nuedexta is a combination of dextromethorphan (DM) and quinidine sulfate. You might reasonably ask why these two agents would have ever been considered as a treatment for PBA.
Read More

Complementary and Alternative Medicine for Mood Disorders

January 1, 2012
Marlene Freeman, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Marlene Freeman, MD Associate professor of psychiatry, Harvard Medical School, Director of clinical services, Perinatal and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital Dr. Freeman has received research support from Lilly, GlaxoSmithKline, and Forest Pharmaceuticals for the study of duloxetine, Lovaza (omega-3 fatty acid), and escitalopram. She has also served as a consultant to Bristol Myers Squibb on measurement based care. Dr. Carlat has reviewed this article and found no evidence of bias in this educational activity.
Defining CAM is challenging. One of the things that makes it so hard to have a concrete discussion on CAM is that it means different things to different people.
Read More

Genes Plus Environment in Psychiatry: View Positive Studies Skeptically

January 1, 2012
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Common sense dictates that genetic predispositions probably interact with life stressors to influence our mental health. Plenty of research has been published to evaluate whether this is actually true, but findings have been mixed.
Read More
Previous 1 2 … 109 110 111 112 113 114 115 116 117 … 176 177 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB7e_Print_App_Access.png

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

    The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2637648401.jpg
    General Psychiatry

    Psychopharm Secrets: Coming Off Meds

    There’s a hidden placebo response to watch for when patients stop meds on their own.
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.